MedTrace Logo

Safety and Efficacy of Low-intensity Laser Therapy in the Treatment of Chronic Musculoskeletal Pain

NCT06009900 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 860

Last updated 2023-08-24

No results posted yet for this study

Summary

This study is a multicenter, prospective, randomized, controlled research design. This study takes classic NSAIDs treatment as a control, and it will take patients' pain relief, functional improvement, sleep quality improvement, and adverse reactions as the main and secondary evaluation indicators to explore the safety and effectiveness of weak laser treatment of chronic musculoskeletal pain, determining the dominant disease in the treatment of Chronic pain.

Conditions

  • Pain, Chronic

Interventions

DEVICE

Low intensity laser treatment

Low intensity laser treatment: Both patients and doctors wear goggles during the irradiation process. Using 810nm (infrared)/658nm (red) dual wavelength output for direct skin contact point irradiation, the maximum output power is 100mW (red)/60mW (infrared). Select the treatment site based on the patient's anatomical positioning (muscle and tendon attachment points, nerve distribution aggregation points) and/or pain points, and perform spot laser irradiation. Low intensity laser treatment process: Treat once a day for 15 minutes each time, with 5 consecutive days of treatment and 2 days of rest per week. The patient received a total of 3 weeks (15 times) of low intensity laser treatment.

DRUG

Non-steroidal drug (Celecoxib) group

Oral Celecoxib 200mg/time, twice a day, for three consecutive weeks.

Sponsors & Collaborators

  • Shanxi Bethune Hospital

    collaborator OTHER

  • Second Hospital of Shanxi Medical University

    collaborator OTHER

  • Shanxi Provincial People's Hospital

    collaborator OTHER_GOV

  • China Resources WISCO General Hospital

    collaborator UNKNOWN

  • LinFen People's Hospital

    collaborator UNKNOWN

  • Tongji Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2023-09-01
Completion
2024-12-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06009900 on ClinicalTrials.gov